Good evidence that intravenous immunoglobulin treatment within the first 10 days of symptoms reduces coronary artery abnormalities (heart damage) in children with Kawasaki disease. Kawasaki disease is ...

Objective To summarise clinical trials that compared the incidence of coronary abnormality between intravenous immune globulin (IVIG) plus corticosteroid therapy and IVIG therapy alone, and to ...

However, whether subcutaneous blinatumomab will enhance efficacy or simply provide additional convenience will ultimately require randomised trials. Furthermore, the increased neurotoxicity requires ...

Impact of different treatment strategies on therapeutic efficacy and biomarkers in children with IVIG-resistant Kawasaki disease: a retrospective cohort study ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat ... CIDP who have previously undergone corticosteroid or ...

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US. 1 Full results ...